- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01453764
Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into Patients With Multiple Sclerosis
August 31, 2017 updated by: Ageless Regenerative Institute
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously Into Patients With Multiple Sclerosis
The intent of this clinical study is to answer the questions:
- Is the proposed treatment safe
- Is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes?
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This will be an open-label, non-randomized multi-center patient sponsored study of Adipose-Derived Stromal Cells (ASC) implantation performed intrathecally and intravenously.
ASCs will be derived from the patient's adipose-derived tissue.
Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Aventura, Florida, United States, 33180
- Ageless Regenerative Institute LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and Females between Age 18 and 80 years.
- Duration of disease: >5 years
- Failure to respond or intolerance to the currently available Multiple Sclerosis (MS) immunomodulatory treatments (ie interferons, Copaxone, immunosuppression): the lack of response to these treatments will be determined/defined by either an increase (deterioration) of at least one degree in the Expanded Disability Status Scale (EDSS) score during the last year or the appearance of at least two major relapses of MS during the same period of time (under treatment) or intolerance to these agents.
- Up to date on all age and gender appropriate cancer screening per American Cancer Society .
Exclusion Criteria:
- Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
- Life expectancy < 6 months due to concomitant illnesses.
- Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
- Active infectious disease. For patients who have tested positive, an expert will be consulted as to patient eligibility based on the patient's infectious status
- Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
- Patients on chronic immunosuppressive transplant therapy
- Systolic blood pressure (supine) ≤90 mmHg;
- Resting heart rate > 100 bpm;
- Active clinical infection.
- Cerebrovascular accident within 6 months prior to study entry
- Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
- History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
- Unwilling and/or not able to give written informed consent.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Adipose SVF IV Infusion
IV Infusion of Autologous Adipose Derived Stromal Vascular Fraction Intervention: Intravenous Infusion
|
The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory.
The Adipose SVF will be delivered via intravenous injection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical improvement in disability score compared to baseline
Time Frame: 3 months
|
3 months
|
|
Number of patients with adverse events
Time Frame: up to 6 months
|
The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 6-month period following treatment.
|
up to 6 months
|
Clinical improvement in disability score compared to baseline
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
MS disease activity measured by the number of Gd-enhancing brain MRI lesions
Time Frame: 3 months
|
3 months
|
Reduced number of relapses or freedom from progression of disease
Time Frame: 3 months
|
3 months
|
Reduced number of relapses or freedom from progression of disease
Time Frame: 6 months
|
6 months
|
MS disease activity measured by the number of Gd-enhancing brain MRI lesions
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2016
Primary Completion (Anticipated)
December 1, 2018
Study Completion (Anticipated)
April 1, 2019
Study Registration Dates
First Submitted
October 3, 2011
First Submitted That Met QC Criteria
October 17, 2011
First Posted (Estimate)
October 18, 2011
Study Record Updates
Last Update Posted (Actual)
September 1, 2017
Last Update Submitted That Met QC Criteria
August 31, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD-US-MS-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nervous System Diseases
-
Bracco Diagnostics, IncCompletedCentral Nervous System Neoplasms | Central Nervous System Disease
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingCentral Nervous System TumorUnited States
-
Bracco Diagnostics, IncCompletedCentral Nervous System Diseases | Central Nervous System NeoplasmsUnited States
-
University of MichiganCompletedAutonomic Peripheral Nervous System DiseasesUnited States
-
Washington University School of MedicineRecruitingCentral Nervous SystemUnited States
-
Weill Medical College of Cornell UniversityRecruitingCentral Nervous System Tumor | Pediatric Central Nervous System TumorUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)TerminatedBrain and Central Nervous System TumorsUnited States
Clinical Trials on Harvesting and Implantation of SVF
-
Ageless Regenerative InstituteWithdrawnDiabetes Mellitus Type IIUnited States
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawn
-
Ageless Regenerative InstituteWithdrawnParkinson's DiseaseUnited States
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnNon-Ischemic Congestive Heart FailureMexico
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnIschemic Congestive Heart FailureMexico
-
Ageless Regenerative InstituteInstituto de Medicina RegenerativaWithdrawnBrain Lesion (General)Mexico
-
Ageless Regenerative InstituteWithdrawnAlzheimer's DiseaseUnited States
-
University of FloridaCompleted
-
Central Clinical Hospital w/Outpatient Health Center...Orenburg Regional Clinical Blood Donor CenterUnknownKnee OsteoarthritisRussian Federation